Can Immunotherapy's hidden toll on daily life be measured?
NCT ID NCT07754409
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This study follows 75 people with locally advanced non-small cell lung cancer who receive a year of adjuvant immunotherapy after chemoradiotherapy. Researchers will use questionnaires to track changes in quality of life and self-reported health from the start of immunotherapy to 12 months later. The goal is to understand how this newer treatment affects patients' daily well-being, so healthcare teams can better support them during and after therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Adjuvant immunotherapy (immune checkpoint inhibitors) after chemoradiotherapy
- What this could lead to
- If successful, this could reveal how adjuvant immunotherapy affects patients' daily lives, guiding better support and care during treatment.
- What could go wrong
- This is a small observational study, so findings may not apply to all patients. It does not test a new treatment, so it won't directly change outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL CARCINOMA OF LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.